Literature DB >> 10728707

Expression of sialyl 6-sulfo Lewis X is inversely correlated with conventional sialyl Lewis X expression in human colorectal cancer.

M Izawa1, K Kumamoto, C Mitsuoka, C Kanamori, A Kanamori, K Ohmori, H Ishida, S Nakamura, K Kurata-Miura, K Sasaki, T Nishi, R Kannagi.   

Abstract

Sialyl 6-sulfo Lewis X determinant has been described recently as a major ligand for L-selectin on high endothelial venules of human peripheral lymph nodes. From our investigation of its distribution in human colorectal cancer tissues and cultured colon cancer cells, the sialyl 6-sulfo Lewis X determinant was preferentially expressed in the nonmalignant colonic epithelia rather than cancer cells (P < 0.001; n = 23). This was in contrast to the distribution of conventional sialyl Lewis X, which was preferentially expressed in cancer tissues rather than nonmalignant epithelia (P = 0.007; n = 23), indicating that 6-sulfation predominantly occurs in nonmalignant tissues and is suppressed upon malignant transformation. In confirmation of this, a nonsialylated determinant 6-sulfo Lewis X was also found to be preferentially localized in the nonmalignant epithelia. Significant expression of sialyl 6-sulfo Lewis X was observed in only 2 lines, whereas 8 were positive for conventional sialyl Lewis X, among 13 cultured colon cancer cell lines. Transfection of cells with fucosyltransferase (Fuc-T) VI induced expression of sialyl 6-sulfo Lewis X, whereas transfection of Fuc-T III did not, suggesting that the determinant was synthesized mainly by Fuc-T VI in colonic epithelia. Members of the sialic acid cyclase pathway, the de-N-acetyl sialyl 6-sulfo Lewis X and cyclic sialyl 6-sulfo Lewis X determinants, were also preferentially expressed in the nonmalignant epithelia rather than colonic cancer cells (P < 0.001; n = 23). Stimulation of the sialyl 6-sulfo Lewis X-positive colon cancer cell line with a calcium ionophore ionomycin markedly reduced sialyl 6-sulfo Lewis X and induced cyclic sialyl 6-sulfo Lewis X expression. These results suggested that the metabolic conversion of sialyl 6-sulfo Lewis X into cyclic sialyl 6-sulfo Lewis X by a calcium-dependent enzyme, sialic acid cyclase, as we hypothesized for human leukocytes previously (C. Mitsuoka et al., Proc. Natl. Acad. Sci. USA, 96: 1597-1602, 1999), also occurs in nonmalignant colonic epithelia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10728707

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Distinct substrate specificities of human GlcNAc-6-sulfotransferases revealed by mass spectrometry-based sulfoglycomic analysis.

Authors:  Shin-Yi Yu; Cheng-Te Hsiao; Mineko Izawa; Akiko Yusa; Hiroji Ishida; Shigeo Nakamura; Hirokazu Yagi; Reiji Kannagi; Kay-Hooi Khoo
Journal:  J Biol Chem       Date:  2018-08-09       Impact factor: 5.157

2.  Fucosylation and gastrointestinal cancer.

Authors:  Kenta Moriwaki; Eiji Miyoshi
Journal:  World J Hepatol       Date:  2010-04-27

3.  Total synthesis of trifluorobutyryl-modified, globally protected sialyl Lewis x by a convergent [2+2] approach.

Authors:  Gizem Akçay; John Y Ramphal; Marc d'Alarcao; Krishna Kumar
Journal:  Tetrahedron Lett       Date:  2015-01-01       Impact factor: 2.415

4.  Alterations in the serum glycome due to metastatic prostate cancer.

Authors:  Zuzana Kyselova; Yehia Mechref; Mohammad M Al Bataineh; Lacey E Dobrolecki; Robert J Hickey; Jake Vinson; Christopher J Sweeney; Milos V Novotny
Journal:  J Proteome Res       Date:  2007-04-14       Impact factor: 4.466

Review 5.  Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.

Authors:  Kayluz Frias Boligan; Circe Mesa; Luis Enrique Fernandez; Stephan von Gunten
Journal:  Cell Mol Life Sci       Date:  2014-12-07       Impact factor: 9.261

6.  Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets.

Authors:  Yehia Mechref; Ahmed Hussein; Slavka Bekesova; Vitara Pungpapong; Min Zhang; Lacey E Dobrolecki; Robert J Hickey; Zane T Hammoud; Milos V Novotny
Journal:  J Proteome Res       Date:  2009-06       Impact factor: 4.466

7.  Anti-oligosaccharide antibodies as tools for studying sulfated sialoglycoconjugate ligands for siglecs and selectins.

Authors:  Reiji Kannagi; Katsuyuki Ohmori; Naoko Kimura
Journal:  Glycoconj J       Date:  2009-11       Impact factor: 2.916

Review 8.  N-acetylglucosamine: production and applications.

Authors:  Jeen-Kuan Chen; Chia-Rui Shen; Chao-Lin Liu
Journal:  Mar Drugs       Date:  2010-09-15       Impact factor: 5.118

Review 9.  Biological modulation by lectins and their ligands in tumor progression and metastasis.

Authors:  Susumu Nakahara; Avraham Raz
Journal:  Anticancer Agents Med Chem       Date:  2008-01       Impact factor: 2.505

Review 10.  Altered sphingolipid metabolism induced by tumor hypoxia - new vistas in glycolipid tumor markers.

Authors:  Jun Yin; Keiko Miyazaki; Rebecca L Shaner; Alfred H Merrill; Reiji Kannagi
Journal:  FEBS Lett       Date:  2009-11-11       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.